Stay updated on ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial
Sign up to get notified when there's something new on the ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial page.

Latest updates to the ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial page
- Check4 days agoChange DetectedThe page’s revision/version label was updated from v3.5.2 to v3.5.3, reflecting a website/system update rather than a change to the study record content.SummaryDifference0.0%

- Check11 days agoChange DetectedThe study status is updated to Completed with new dates (2026-04-15; 2026-03-05; 2026-04-07; 2026-04) and revision v3.5.2, and the previous Active, not recruiting status along with its earlier dates and revision v3.5.0 were removed.SummaryDifference0.4%

- Check18 days agoNo Change Detected
- Check40 days agoChange DetectedSite revision tag updated to Revision: v3.5.0, replacing Revision: v3.4.3.SummaryDifference0.0%

- Check47 days agoChange DetectedRevision updated to v3.4.3, replacing v3.4.2.SummaryDifference0.0%

- Check75 days agoChange DetectedUpdated study details add a core biopsy requirement for ER IHC and PD testing, and introduce dose escalation with an RP2D plus a palbociclib combination cohort. ARV-471 dosing for Parts A and B is now specified as QD or BID for 28-day cycles, with pharmacokinetic endpoints (AUC) included.SummaryDifference0.8%

- Check83 days agoChange DetectedAdded a government funding lapse notice indicating NIH Clinical Center status and updated the system revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial page.